DK3619324T3 - Rekombinante modificerede fibroblast-vækstfaktorer og terapeutiske anvendelser heraf - Google Patents
Rekombinante modificerede fibroblast-vækstfaktorer og terapeutiske anvendelser herafInfo
- Publication number
- DK3619324T3 DK3619324T3 DK18794391.5T DK18794391T DK3619324T3 DK 3619324 T3 DK3619324 T3 DK 3619324T3 DK 18794391 T DK18794391 T DK 18794391T DK 3619324 T3 DK3619324 T3 DK 3619324T3
- Authority
- DK
- Denmark
- Prior art keywords
- growth factors
- fibroblast growth
- therapeutic applications
- recombinant modified
- modified fibroblast
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]
- C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502529P | 2017-05-05 | 2017-05-05 | |
| US201762502540P | 2017-05-05 | 2017-05-05 | |
| US201762584624P | 2017-11-10 | 2017-11-10 | |
| PCT/US2018/031189 WO2018204847A2 (en) | 2017-05-05 | 2018-05-04 | Recombinant modified fibroblast growth factors and therapeutic uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3619324T3 true DK3619324T3 (da) | 2025-09-22 |
Family
ID=64016756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18794391.5T DK3619324T3 (da) | 2017-05-05 | 2018-05-04 | Rekombinante modificerede fibroblast-vækstfaktorer og terapeutiske anvendelser heraf |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11479591B2 (enExample) |
| EP (2) | EP4621067A3 (enExample) |
| JP (2) | JP2020518287A (enExample) |
| KR (1) | KR20200078425A (enExample) |
| CN (1) | CN111148755A (enExample) |
| AU (1) | AU2018261021B2 (enExample) |
| BR (1) | BR112019023260A2 (enExample) |
| CA (1) | CA3062473A1 (enExample) |
| DK (1) | DK3619324T3 (enExample) |
| ES (1) | ES3041527T3 (enExample) |
| MX (1) | MX2019013210A (enExample) |
| WO (1) | WO2018204847A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4621067A3 (en) | 2017-05-05 | 2025-11-19 | Trefoil Therapeutics, Inc. | Recombinant modified fibroblast growth factors and therapeutic uses thereof |
| JP2023532046A (ja) * | 2020-06-26 | 2023-07-26 | トレフォイル セラピューティクス，インク． | 組換え修飾線維芽細胞増殖因子およびそれを使用した治療 |
| WO2021261946A1 (ko) | 2020-06-26 | 2021-12-30 | 엘티소재주식회사 | 헤테로고리 화합물 및 이를 이용한 유기 발광 소자 |
| WO2022241465A1 (en) * | 2021-05-14 | 2022-11-17 | Claris Biotherapeutics, Inc. | Compositions of growth factor for the treatment of eye disease |
| CN113289005B (zh) * | 2021-07-06 | 2022-05-31 | 温州医科大学 | rhFGF-21在制备治疗干眼症药物中的应用 |
| WO2023019218A1 (en) * | 2021-08-12 | 2023-02-16 | Trefoil Therapeutics, Inc. | Modified fibroblast growth factors for treating fibrotic diseases |
| US12357843B2 (en) | 2022-03-25 | 2025-07-15 | Cutera, Inc. | Methods of skin treatment with laser light |
| CN115177717A (zh) * | 2022-08-31 | 2022-10-14 | 贵州医科大学附属医院 | 一种治疗眼表及角膜上皮疾病的药物 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552528A (en) * | 1986-03-03 | 1996-09-03 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bovine b-endothelial cell growth factor |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| GB2223496B (en) * | 1988-08-08 | 1992-05-27 | British Bio Technology | Synthetic gene encoding mature human acid fibroblast growth factor |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| GB9523946D0 (en) | 1995-11-23 | 1996-01-24 | Bayer Ag | Leukotriene antagonistic benzoic acid derivatives |
| US20010006939A1 (en) | 1997-10-03 | 2001-07-05 | Ralph W. Niven | Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions |
| US6642026B2 (en) * | 2000-08-15 | 2003-11-04 | Phage Biotechnology Corporation | Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis |
| AU1628101A (en) | 1999-11-22 | 2001-06-04 | Millennium Pharmaceuticals, Inc. | Jaffa, a novel fibroblast growth factor family member and uses therefor |
| WO2005048942A2 (en) | 2003-11-13 | 2005-06-02 | Pharmacia Corporation | Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent |
| US7790682B1 (en) | 2003-12-02 | 2010-09-07 | The Florida State University Research Foundation, Inc. | Engineered human acidic fibroblast growth factors and associated methods |
| BRPI0416683A (pt) * | 2003-12-10 | 2007-01-30 | Lilly Co Eli | muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21 |
| EP1634877B1 (en) * | 2004-08-17 | 2011-06-22 | Simpson Biotech Co., Ltd. | Mixture and compounds from mycelia of antrodia camphorata and use thereof |
| US7595296B1 (en) | 2006-11-09 | 2009-09-29 | Florida State University Research Foundation, Inc. | Mutant polypeptides of fibroblast growth factor 1 |
| US7659379B1 (en) | 2007-05-24 | 2010-02-09 | Florida State University Research Foundation, Inc. | Mutants of human fibroblast growth factor having increased stability and/or mitogenic potency |
| NZ601868A (en) * | 2008-01-22 | 2014-05-30 | Araim Pharmaceuticals Inc | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage |
| US8461111B2 (en) | 2009-05-20 | 2013-06-11 | Florida State University Research Foundation | Fibroblast growth factor mutants having improved functional half-life and methods of their use |
| US20110224404A1 (en) | 2010-03-11 | 2011-09-15 | Florida State University Research Foundation | Method for development of a peptide building block useful for de novo protein design |
| US9006400B2 (en) * | 2011-09-26 | 2015-04-14 | Novartis Ag | Fibroblast growth factor-21-Fc fusion proteins |
| US20150253308A1 (en) * | 2013-05-03 | 2015-09-10 | Orasis | Compositions and methods of treating glaucoma |
| WO2015048188A2 (en) * | 2013-09-25 | 2015-04-02 | Trefoil Therapeutics, Llc | Modified fibroblast growth factors for the treatment of ocular disorders |
| TWI634898B (zh) * | 2013-10-07 | 2018-09-11 | 雅祥生技醫藥股份有限公司 | 經修飾之人類酸性纖維母細胞生長因子及其組合物 |
| US20150104494A1 (en) * | 2013-10-11 | 2015-04-16 | Ohio State Innovation Foundation | Methods for repair of ear canal tissue defects |
| JP6621752B2 (ja) | 2013-10-21 | 2019-12-18 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法 |
| WO2015198175A1 (en) | 2014-06-27 | 2015-12-30 | Florida State University Research Foundation, Inc. | Design of fgf-1 mutants to effectively eliminate reactive cysteine residues |
| WO2016172153A2 (en) | 2015-04-20 | 2016-10-27 | Salk Institute For Biological Studies | Fibroblast growth factor (fgf) 1 with mutation in the heparin binding domain and methods of use to reduce blood glucose |
| CA2983268A1 (en) * | 2015-04-20 | 2016-10-27 | Salk Institute For Biological Studies | Fibroblast growth factor (fgf) 1 mutants and methods of use to reduce blood glucose |
| EP3336178B1 (en) * | 2015-08-13 | 2020-03-18 | Fujifilm Corporation | Method for culturing pluripotent stem cells, method for manufacturing culture vessel, culture vessel, and scaffold material for culturing cells |
| EP4621067A3 (en) | 2017-05-05 | 2025-11-19 | Trefoil Therapeutics, Inc. | Recombinant modified fibroblast growth factors and therapeutic uses thereof |
-
2018
- 2018-05-04 EP EP25181506.4A patent/EP4621067A3/en active Pending
- 2018-05-04 MX MX2019013210A patent/MX2019013210A/es unknown
- 2018-05-04 US US16/611,182 patent/US11479591B2/en active Active
- 2018-05-04 CA CA3062473A patent/CA3062473A1/en active Pending
- 2018-05-04 ES ES18794391T patent/ES3041527T3/es active Active
- 2018-05-04 BR BR112019023260-5A patent/BR112019023260A2/pt not_active IP Right Cessation
- 2018-05-04 CN CN201880044863.5A patent/CN111148755A/zh active Pending
- 2018-05-04 KR KR1020197035895A patent/KR20200078425A/ko not_active Ceased
- 2018-05-04 DK DK18794391.5T patent/DK3619324T3/da active
- 2018-05-04 WO PCT/US2018/031189 patent/WO2018204847A2/en not_active Ceased
- 2018-05-04 JP JP2020511867A patent/JP2020518287A/ja active Pending
- 2018-05-04 EP EP18794391.5A patent/EP3619324B1/en active Active
- 2018-05-04 AU AU2018261021A patent/AU2018261021B2/en active Active
-
2022
- 2022-09-07 US US17/939,238 patent/US20230130851A1/en active Pending
-
2024
- 2024-05-07 JP JP2024075396A patent/JP2024112824A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018261021B2 (en) | 2024-09-12 |
| US11479591B2 (en) | 2022-10-25 |
| JP2020518287A (ja) | 2020-06-25 |
| EP3619324A2 (en) | 2020-03-11 |
| ES3041527T3 (en) | 2025-11-12 |
| EP3619324B1 (en) | 2025-07-09 |
| US20230130851A1 (en) | 2023-04-27 |
| MX2019013210A (es) | 2020-07-20 |
| BR112019023260A2 (pt) | 2022-02-22 |
| RU2019139358A (ru) | 2021-06-07 |
| US20200190158A1 (en) | 2020-06-18 |
| CA3062473A1 (en) | 2018-11-08 |
| JP2024112824A (ja) | 2024-08-21 |
| WO2018204847A2 (en) | 2018-11-08 |
| EP4621067A3 (en) | 2025-11-19 |
| KR20200078425A (ko) | 2020-07-01 |
| EP3619324A4 (en) | 2020-12-30 |
| RU2019139358A3 (enExample) | 2021-08-26 |
| AU2018261021A1 (en) | 2019-12-12 |
| CN111148755A (zh) | 2020-05-12 |
| EP4621067A2 (en) | 2025-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3619324T3 (da) | Rekombinante modificerede fibroblast-vækstfaktorer og terapeutiske anvendelser heraf | |
| IL268593A (en) | Polypeptide variants and uses thereof | |
| DK3784283T3 (da) | Cannabidiopræparater og anvendelser deraf | |
| PL3661954T3 (pl) | Muteiny interleukiny 21 i sposoby leczenia | |
| EP3576765A4 (en) | TARGETED ENGINEERING INTERFERON AND USES OF IT | |
| DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
| DK3412302T3 (da) | Modificerede fgf-21-polypeptider og anvendelser deraf | |
| DK3988117T3 (da) | Terapeutiske antistoffer og deres anvendelser | |
| DK3668512T3 (da) | Pyruvatkinasemodulatorer og anvendelse deraf | |
| DK3322430T3 (da) | Antiinflammatoriske peptider, og anvendelser deraf | |
| DK3678687T3 (da) | Mutant fgf-21 peptidkonjugater og anvendelser deraf | |
| EP3893945A4 (en) | CROMOGLYC ESTERS AND THEIR USES | |
| DK3618848T3 (da) | Biologisk aktive komplekser og terapeutiske anvendelser deraf | |
| DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
| DK3743106T3 (da) | Influenzavirusvacciner og anvendelser deraf | |
| DK3325618T3 (da) | Hidtil ukendte trypsin-isoformer og anvendelse deraf | |
| EP3615058A4 (en) | KETOREDUCTASE-POLYPEPTIDES AND POLYNUCLEOTIDES | |
| EP3723771A4 (en) | Recombinant adenoviruses and uses thereof | |
| EP3570867A4 (en) | THERAPEUTIC PEPTIDES AND NEUROPROTECTORS | |
| DK3737399T5 (da) | Atf5-peptidvarianter og anvendelser deraf | |
| DK3589674T3 (da) | Silikone-urethan-urea-copolymer og fremstilling og anvendelse deraf | |
| DK3720875T3 (da) | Antimikrobielle peptider og fremgangsmåder til anvendelse deraf | |
| SG11201912799SA (en) | Recombinant human-basic fibroblast growth factor (rh-bfgf) and pharmaceutical composition comprising rh-bfgf | |
| DK3635102T3 (da) | B4galt1-varianter og anvendelser deraf | |
| DK3590523T3 (da) | Vækstfremmende peptider og anvendelser deraf |